Valion Bio achieves first milestone under Statera license; issues preferred shares for $750K payment

Valion Bio, Inc.

Achieved first milestone: validation of inventory for distribution and sales, triggering $750K payment.
Issued 1,287.8685 Series A Preferred shares to Statera and Avenue as partial consideration.
Milestone relates to Entolimod for Acute Radiation Syndrome (ARS) under A&R License Agreement.
Remaining ARS milestones total $1.75M; Neutropenia milestones up to $2.75M if option exercised.
Securities issued as unregistered, exempt under Section 4(a)(2) and Regulation D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.